Drug Type Small molecule drug, Diagnostic radiopharmaceuticals |
Synonyms FluoroTau, 3H-THK5351, F-18 THK-5351 + [4] |
Target |
Action inhibitors |
Mechanism TAU inhibitors(Microtubule-associated protein tau inhibitors) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
License Organization- |
Drug Highest PhasePendingPhase 2 |
First Approval Date- |
Regulation- |
Molecular FormulaC18H18FN3O2 |
InChIKeyDLVXFZWSPCOWSN-DHZJDKHOSA-N |
CAS Registry1707148-68-2 |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Neuroinflammation | Phase 2 | Taiwan Province | 01 Nov 2020 | |
| Depressive Disorder, Major | Phase 2 | Taiwan Province | 23 Mar 2018 | |
| Alzheimer Disease | Phase 2 | United States | 11 Jan 2016 | |
| Dementia | Phase 2 | Taiwan Province | 04 Jan 2016 | |
| Mild cognitive disorder | Phase 2 | Taiwan Province | 04 Jan 2016 | |
| Plaque, Amyloid | Phase 2 | Taiwan Province | 04 Jan 2016 | |
| Stroke | Phase 2 | Taiwan Province | 04 Jan 2016 |
Phase 2 | 17 | Lumbar Puncture (optional)+18F-THK-5351 (Cognitive Impairment) | lzqvoremcw(gcoyvztjxr) = cuaqymnumh ljzmxptlbf (ufxeaekxpf, xvlktxnwdi - eltbwaexvc) View more | - | 19 Nov 2018 | ||
Lumbar Puncture (optional)+18F-THK-5351 (No Cognitive Impairment) | lzqvoremcw(gcoyvztjxr) = zjjttomsrq ljzmxptlbf (ufxeaekxpf, qbqdvtdvaw - ibxabyhidn) View more | ||||||
Phase 1 | - | 12 | fgxllbafdd(fnxfacxxhc) = kbcagigtpq axavnrmosu (ngyzwcvlfz ) | - | 01 Sep 2017 |





